A new radiotracer, 18F-SynVesT-2, can directly assess synaptic density changes in the brain, providing an objective and quantitative measure of disease progression after stroke. Research presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting shows that the radiotracer may also offer a primary endpoint to evaluate treatment efficacy of novel therapeutics for stroke in clinical trials.
- Researchers develop a simplified method to modify disease signaling with light
- Relieving the cost of COVID-19 by Parrondo’s paradox
- Enzyme biofactories to enhance cord blood transplants
- Reviewing multiferroics for future, low-energy data storage
- COVID-19 study: Meaning in life and self-control protect against stress